CTKB (Cytek Biosciences) Shares Outstanding (EOP): 129.1 Mil (As of Mar. 2026)


CTKB Cytek Biosciences Inc CTKB
71 GF Score
Price $4.46
GF Value $5.82
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cytek Biosciences Shares Outstanding (EOP)?

Cytek Biosciences CTKB +0.11% 71 Shares Outstanding (EOP) is 129.1 Mil as of Mar. 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cytek Biosciences's shares outstanding for the quarter that ended in Mar. 2026 was 129.1 Mil.

Cytek Biosciences's quarterly shares outstanding increased from Dec. 2025 (128.6 Mil) to Mar. 2026 (129.1 Mil). It means Cytek Biosciences issued new shares from Dec. 2025 to Mar. 2026 .

Cytek Biosciences's annual shares outstanding declined from Dec. 2024 (129.2 Mil) to Dec. 2025 (128.6 Mil). It means Cytek Biosciences bought back shares from Dec. 2024 to Dec. 2025 .


Cytek Biosciences  (NAS:CTKB) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Cytek Biosciences Shares Outstanding (EOP) Related Terms


Cytek Biosciences Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Cytek Biosciences's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytek Biosciences Shares Outstanding (EOP) Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 133.75 135.37 130.72 129.21 128.55

Cytek Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.60 127.19 127.87 128.55 129.14

CTKB vs BBNX, TCMD, NPCE: Shares Outstanding (EOP) Comparison

For the Medical Devices subindustry, Cytek Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytek Biosciences Shares Outstanding (EOP) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Shares Outstanding (EOP) falls into.


CTKB
71GF Score
Cytek Biosciences Inc CTKB
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytek Biosciences Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 129.1 Mil mean?
Cytek Biosciences (CTKB) has a Shares Outstanding (EOP) of 129.1 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Cytek Biosciences and its competitors.
Is Cytek Biosciences' Shares Outstanding (EOP) too high?
Cytek Biosciences' current Shares Outstanding (EOP) is 129.1 Mil. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Shares Outstanding (EOP) compare to BBNX and TCMD?
Cytek Biosciences' Shares Outstanding (EOP) of 129.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Devices & Instruments company?
A good Shares Outstanding (EOP) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Cytek Biosciences and its competitors. Cytek Biosciences's current Shares Outstanding (EOP) is 129.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.46 — trading 23.4% below its estimated fair value. The current Shares Outstanding (EOP) is 129.1 Mil. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Shares Outstanding (EOP) is 129.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytek Biosciences (CTKB) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of $4.46 is trading 23.4% below its estimated GF Value™ of $5.82. GuruFocus considers Cytek Biosciences to be Modestly Undervalued.

Key valuation signals for CTKB:

  • Shares Outstanding (EOP): 129.1 Mil
  • GF Value™: $5.82 vs. price of $4.46 (23.4% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cytek Biosciences Business Description

Other Exchanges 8EQ:Germany
Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score

Get the complete analysis for CTKB

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.46
Price
$5.82
GF Value